Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
Background/purpose ::: Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most popular oral antidiabetic drugs (OADs) in recent 20 years because of the low risk of hypoglycemia, intermediate efficacy to lower glycated hemoglobin (△HbA1c): 0.5–0.9%, neutral effect on body weight change, convenience for usage (mostly once daily), and rare occurrence of major side effects. The purpose of this study was to determine the important predictors of the efficacy of naive use of DPP-4 inhibitors in Taiwanese patients with type 2 diabetes mellitus (T2D).
Advanced metal barrier free (MBF) Cu dual damascene interconnects (DDIs) have been successfully fabricated using a low-k CVD OSG (k=2.5) and PECVD silicon carbides for the first time. With PECVD silicon carbides replacing TaN, the Cu DDIs thus built showed 8% better in interconnect RC delay, 36% lower in via resistance and three orders of magnitude lower in line-line leakage at 200/spl deg/C. The newly developed technology also enhanced Cu TDDB lifetime by more than three orders of magnitude. On the MBF DDIs, 15%-faster 90-nm CMOS device operation has been achieved, which makes the newly developed MBF Cu DDI technology promising for high performance sub-90 nm CMOS devices and beyond.